BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,530,936 | -18.1% | 580,739 | -1.7% | 0.05% | -14.5% |
| Q2 2023 | $48,238,921 | -9.3% | 590,946 | -17.6% | 0.06% | -9.8% |
| Q1 2023 | $53,210,915 | +3.0% | 717,225 | +15.1% | 0.06% | 0.0% |
| Q4 2022 | $51,637,531 | +41.0% | 622,987 | +383.1% | 0.06% | +29.8% |
| Q3 2022 | $36,623,000 | -18.6% | 128,955 | -0.6% | 0.05% | -16.1% |
| Q2 2022 | $44,991,000 | -40.2% | 129,793 | -25.3% | 0.06% | -27.3% |
| Q1 2022 | $75,222,000 | -24.1% | 173,706 | -9.3% | 0.08% | -19.8% |
| Q4 2021 | $99,077,000 | -7.2% | 191,512 | -13.1% | 0.10% | -16.5% |
| Q3 2021 | $106,797,000 | +0.1% | 220,394 | -7.0% | 0.12% | -0.9% |
| Q2 2021 | $106,733,000 | +2.4% | 237,047 | -13.2% | 0.12% | -7.9% |
| Q1 2021 | $104,262,000 | +23.4% | 272,988 | +2.6% | 0.13% | +12.5% |
| Q4 2020 | $84,510,000 | -0.1% | 266,131 | -22.0% | 0.11% | -17.0% |
| Q3 2020 | $84,571,000 | -19.9% | 341,384 | -14.6% | 0.14% | -26.2% |
| Q2 2020 | $105,620,000 | +54.5% | 399,969 | +10.9% | 0.18% | +18.1% |
| Q1 2020 | $68,381,000 | +12.9% | 360,623 | +30.7% | 0.16% | +50.5% |
| Q4 2019 | $60,577,000 | -22.8% | 275,965 | -31.2% | 0.10% | -30.4% |
| Q3 2019 | $78,440,000 | -39.4% | 400,879 | -35.4% | 0.15% | -39.3% |
| Q2 2019 | $129,428,000 | -2.9% | 620,787 | -7.6% | 0.24% | -7.9% |
| Q1 2019 | $133,345,000 | +23.2% | 671,595 | -10.2% | 0.26% | +3.1% |
| Q4 2018 | $108,226,000 | -21.2% | 747,827 | +11.1% | 0.26% | +0.4% |
| Q3 2018 | $137,359,000 | +94.6% | 672,964 | +41.1% | 0.26% | +75.3% |
| Q2 2018 | $70,574,000 | +12.5% | 477,014 | +14.8% | 0.15% | +1.4% |
| Q1 2018 | $62,733,000 | +17.8% | 415,340 | +1.1% | 0.14% | +13.4% |
| Q4 2017 | $53,244,000 | +21.8% | 410,991 | +13.7% | 0.13% | +13.4% |
| Q3 2017 | $43,704,000 | +22.1% | 361,521 | +18.6% | 0.11% | +16.7% |
| Q2 2017 | $35,808,000 | +12.4% | 304,746 | -2.8% | 0.10% | +9.1% |
| Q1 2017 | $31,858,000 | +4.9% | 313,410 | +6.1% | 0.09% | -2.2% |
| Q4 2016 | $30,379,000 | -38.7% | 295,430 | -34.7% | 0.09% | -39.2% |
| Q3 2016 | $49,548,000 | +4.1% | 452,490 | +7.2% | 0.15% | -1.3% |
| Q2 2016 | $47,600,000 | +38.1% | 422,099 | +15.7% | 0.15% | +35.1% |
| Q1 2016 | $34,474,000 | -73.2% | 364,732 | -74.4% | 0.11% | -66.7% |
| Q4 2015 | $128,476,000 | +10.6% | 1,427,509 | +13.7% | 0.33% | -0.9% |
| Q3 2015 | $116,126,000 | -22.9% | 1,255,956 | -17.9% | 0.34% | -14.1% |
| Q2 2015 | $150,651,000 | +45.4% | 1,529,920 | +48.1% | 0.39% | +28.6% |
| Q1 2015 | $103,597,000 | +5.4% | 1,032,977 | -2.8% | 0.30% | -8.2% |
| Q4 2014 | $98,244,000 | – | 1,063,244 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |